Preferential incorporation of shorter and less unsaturated acyl phospholipids into high density lipoprotein-like particles in the ABCA1- and ABCA7-mediated biogenesis with apoA-I

Hotta, Nigishi; Abe-Dohmae, Sumiko; Taguchi, Ryo; Yokoyama, Shinji

doi:10.1016/j.chemphyslip.2015.01.005

Cited by 10 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reconstituted ABCA1 in liposomes transfers sphingomyelin from the cytoplasmic to exoplasmic leaflet 20 . HEK293 cells over-expressing ABCA1, ABCA7 or ABCG1 and incubated with apoA-I efflux sphingomyelin 21–23 . However, there is little evidence that their basal levels play a role in sphingomyelin release.…”

Section: Sphingomyelinmentioning

confidence: 99%

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Iqbal

Walsh

Hammad

et al. 2017

Trends in Endocrinology & Metabolism

195

160

View full text Add to dashboard Cite

Sphingolipids are structurally and functionally diverse molecules with significant physiologic functions and are found associated with cellular membranes and plasma lipoproteins. The cellular and plasma concentrations of sphingolipids are altered in several metabolic disorders and may serve as prognostic and diagnostic markers. Here, we discuss different sphingolipid transport mechanisms and highlight how changes in cellular and plasma sphingolipids levels contribute to cardiovascular disease, obesity, diabetes, insulin resistance and nonalcoholic fatty liver disease. Understanding mechanisms involved in intracellular transport, secretion and extracellular transport may provide novel information that might be amenable to therapeutic targeting in the treatment of various metabolic disorders.

show abstract

Section: Sphingomyelinmentioning

confidence: 99%

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Iqbal

Walsh

Hammad

et al. 2017

Trends in Endocrinology & Metabolism

195

160

View full text Add to dashboard Cite

show abstract

“…Under certain circumstances a lipidpoor apoA-I particle (preβ1-HDL) comprising a single apoA-I molecule and 3-4 PL molecules and 1-2 FC molecules is produced (144). The discoidal HDL particles consist of a segment of PL/FC bilayer stabilized by apoA-I wrapped around the edge (113) and contain various species of PL molecules (40, 60, 135,138,[145][146][147][148][149]. PC is the predominant class of PL incorporated into these nascent HDL particles followed by SM and various types of acidic PL to a lesser extent.…”

Section: Characterization Of Nascent Hdlmentioning

confidence: 99%

Is ABCA1 a lipid transfer protein?

Phillips

2018

Journal of Lipid Research

138

128

View full text Add to dashboard Cite

“… 70 In addition to cholesterol efflux, ABCA1 receptors also mediate efflux of sphingomyelin and phosphatidylcholine. 71 , 72 Thus, it is possible that CSL112 infusion, which increases ABCA1‐dependent cholesterol efflux, 7 may alter the phospholipid composition of lipid rafts by increasing cellular efflux of other lipid species. This may also contribute to the observed anti‐inflammatory effects of CSL112, especially given that sphingomyelin depletion has been shown to reduce recruitment of toll‐like receptor 4 to the cell surface of macrophages and attenuate lipopolysaccharide‐induced inflammatory responses.…”

Section: Atheroprotective Effects Of Csl112mentioning

confidence: 99%

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

Kingwell

Nicholls

Velkoska

et al. 2022

JAHA

View full text Add to dashboard Cite

Approximately 12% of patients with acute myocardial infarction (AMI) experience a recurrent major adverse cardiovascular event within 1 year of their primary event, with most occurring within the first 90 days. Thus, there is a need for new therapeutic approaches that address this 90‐day post‐AMI high‐risk period. The formation and eventual rupture of atherosclerotic plaque that leads to AMI is elicited by the accumulation of cholesterol within the arterial intima. Cholesterol efflux, a mechanism by which cholesterol is removed from plaque, is predominantly mediated by apolipoprotein A‐I, which is rapidly lipidated to form high‐density lipoprotein in the circulation and has atheroprotective properties. In this review, we outline how cholesterol efflux dysfunction leads to atherosclerosis and vulnerable plaque formation, including inflammatory cell recruitment, foam cell formation, the development of a lipid/necrotic core, and degradation of the fibrous cap. CSL112, a human plasma‐derived apolipoprotein A‐I, is in phase 3 of clinical development and aims to reduce the risk of recurrent cardiovascular events in patients with AMI in the first 90 days after the index event by increasing cholesterol efflux. We summarize evidence from preclinical and clinical studies suggesting that restoration of cholesterol efflux by CSL112 can stabilize plaque by several anti‐inflammatory/immune‐regulatory processes. These effects occur rapidly and could stabilize vulnerable plaques in patients who have recently experienced an AMI, thereby reducing the risk of recurrent major adverse cardiovascular events in the high‐risk early post‐AMI period.

show abstract

Preferential incorporation of shorter and less unsaturated acyl phospholipids into high density lipoprotein-like particles in the ABCA1- and ABCA7-mediated biogenesis with apoA-I

Cited by 10 publications

References 45 publications

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Is ABCA1 a lipid transfer protein?

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

Contact Info

Product

Resources

About